Stem Cell & Gene Therapy Under Central Drug Regulation

Stem Cell, Gene Therapy and Xenografts: Why India Brought Cutting-Edge Treatments Under Central Drug Regulation

The Central government’s amendment to the Drugs Rules, 1945, announced in July 2026, marks a pivotal moment in India’s approach to biomedical regulation. By bringing stem-cell-derived products, gene-therapeutic products and xenografts under the Central Licensing Approving Authority (CLAA) framework, the Health Ministry has acknowledged what scientists and patient advocates have argued for years: that the country’s existing regulatory architecture was not designed for a world where doctors can re-engineer a patient’s own immune cells to fight cancer.

For CLAT aspirants, this development is a rich intersection of constitutional law, administrative regulation, intellectual property rights and the evolving right to health. Understanding why India acted, and what legal scaffolding it used, is essential preparation for any current-affairs-based legal reasoning question.

What Happened: The Regulatory Amendment in Brief

The Drugs and Cosmetics Act, 1940, is the foundational statute governing drugs, cosmetics and medical devices in India. Its subsidiary legislation, the Drugs Rules, 1945, specifies how licensing, manufacturing, testing and distribution are to be administered. Prior to this amendment, cell and gene therapies — a category that barely existed when the 1940 Act was enacted — operated in a regulatory grey zone.

The amendment does three things:

• Classification: It formally designates stem-cell-derived products, gene-therapeutic products and xenografts (animal-tissue-derived products, such as porcine heart valves) as distinct regulatory categories.
• Central oversight: It places these products under the CLAA framework, meaning approval must come from the central drug regulator — the Central Drugs Standard Control Organisation (CDSCO) — rather than state licensing authorities alone.
• Joint supervision: These therapies now join a select class of products — vaccines, large-volume parenterals and recombinant DNA (r-DNA) medicines — that are subject to both central and state regulatory oversight. This “joint” model reflects the constitutional complexity of health regulation in India.

The Health Ministry has stated that the goal is to allow quicker and safer adoption of emerging technologies while maintaining rigorous patient safety standards. In other words, the amendment is simultaneously enabling and restrictive: it opens a clearer pathway for approval while raising the bar for who can approve and how.

Understanding the Technology: What Are These Therapies?

Before examining the legal dimensions, a brief explanation of the technologies is necessary for any student seeking to write intelligently about this issue.

Gene Therapy

Gene therapy involves introducing, altering or replacing genetic material within a patient’s cells to treat or prevent disease. Unlike conventional drugs, which act on proteins or biological targets, gene therapies intervene at the level of DNA itself. This makes them extraordinarily powerful — and also highly complex. Early gene therapies were plagued by unintended immune reactions; regulatory scrutiny is therefore justified.

CAR-T Cell Therapy

Chimeric antigen receptor T-cell (CAR-T) therapy is among the most exciting applications of gene therapy in oncology. A patient’s T-cells — a type of immune cell — are extracted, genetically modified in a laboratory to “see” and attack cancer cells, and then reinfused into the patient. CAR-T therapies have shown remarkable results in treating blood cancers such as acute lymphoblastic leukaemia and diffuse large B-cell lymphoma. Several Indian companies, including those building on publicly funded research, are developing domestic CAR-T therapies. However, imported patented versions can cost upwards of ₹3–4 crore per patient — rendering them inaccessible to the vast majority of India’s population.

Stem-Cell-Derived Products

Stem cells are undifferentiated cells capable of developing into specialised cell types. Stem-cell-derived products encompass a range from bone marrow transplants (a relatively established therapy) to novel therapies using induced pluripotent stem cells (iPSCs) that are still experimental.

Xenografts

Xenografts are biological materials derived from animal tissue — for example, heart valves harvested from pigs and used in human cardiac surgery. They carry their own regulatory complexity because they straddle the boundary between medical devices and biological products.

The Legal Architecture: CLAA, the Drugs and Cosmetics Act, and Cooperative Federalism

The Drugs and Cosmetics Act, 1940, divides regulatory responsibilities between the Centre and states. Schedule C and C1 of the Drugs Rules, 1945, list products of special regulatory significance — biologicals, vaccines and large-volume parenterals — whose manufacture and import require central approval. The amendment extends this list to include cell and gene therapies and xenografts.

The CLAA is the central authority that grants manufacturing licences for these scheduled products. Before any Indian company can commercially manufacture a gene therapy product, it must obtain CLAA clearance — a process involving clinical trial data, safety reviews and manufacturing standards assessment. This is analogous to the Food and Drug Administration (FDA) approval process in the United States, though with a distinctly Indian federal dimension.

Cooperative Federalism in Health Regulation

Health is a State subject under the Seventh Schedule of the Constitution (Entry 6, State List). However, drugs and poisons are a Concurrent subject (Entry 19, Concurrent List), allowing both Parliament and state legislatures to legislate, with central law prevailing in case of conflict. The “joint supervision” model in the Drugs Rules operationalises this constitutional framework: while the Centre sets standards and grants central licences, state drug controllers retain jurisdiction over retail and distribution within their territories. This is cooperative federalism in practice — an arrangement where both levels of government must work together for the regulatory system to function.

The amendment is noteworthy precisely because it centralises approval for novel therapies while preserving state roles in distribution and post-market surveillance. This balance matters: a purely centralised system might be efficient but would override state expertise in local manufacturing clusters; a purely state-based system could lead to inconsistent standards across the country.

The Right to Health and Access to Medicines

The right to health in India is not an express fundamental right under Part III of the Constitution. However, the Supreme Court has repeatedly read it into Article 21 (right to life) through its expansive interpretation. In Paschim Banga Khet Mazdoor Samity v State of West Bengal (1996), the Court held that the state has an obligation to provide adequate medical facilities. In Vincent Panikurlangara v Union of India (1987), it upheld the state’s power to regulate drug quality as an aspect of the right to life.

The access-to-medicines dimension of CAR-T therapy is particularly acute. When patented therapies cost several crore rupees, the right to health becomes hollow for most patients. India’s compulsory licensing provisions under the Patents Act, 1970 (Section 84) offer a legal mechanism to address this: the government can compel a patent holder to license the technology to domestic manufacturers at a reasonable royalty if the drug is not reasonably available or is unaffordably priced. However, this tool has been used sparingly and controversially. A domestic CAR-T therapy, if developed successfully by Indian companies, could sidestep this tension altogether — and the amended regulatory framework creates a pathway for such development.

The Precautionary Principle and Patient Safety

Regulatory law, particularly in the health sector, is often governed by the precautionary principle: where scientific uncertainty exists about potential harm, regulators may act to prevent that harm even in the absence of conclusive evidence. Cell and gene therapies, precisely because they intervene at the genetic level, carry risks that conventional pharmacovigilance frameworks are not designed to detect or manage — including delayed immune reactions, off-target genetic edits, and insertional mutagenesis.

The CLAA framework, with its requirement for clinical data and manufacturing standards, embodies the precautionary principle. The amendment signals that India intends to regulate with the sophistication these therapies demand — not by blocking innovation, but by channelling it through rigorous oversight.

Key CLAT Concepts to Note

• The Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945, as the primary regulatory framework.
• The CLAA as the central licensing body under the CDSCO.
• Cooperative federalism in health regulation — drugs as a Concurrent List subject, health as a State List subject.
• Article 21 and the judicially evolved right to health.
• Section 84 of the Patents Act, 1970, on compulsory licensing as a tool for improving access to medicines.
• The precautionary principle in administrative and environmental law, applied here to biomedical regulation.

Conclusion: Regulation as an Enabler

The amendment to the Drugs Rules, 1945, is not a simple addition to a list. It reflects a deliberate policy choice to treat cell and gene therapies as a category requiring the same level of centralised scrutiny as vaccines — products whose safety cannot be left to fragmented state-level oversight. At the same time, by creating a clear licensing pathway, the government is signalling to Indian biotech companies that the regulatory road is now mapped, even if it is demanding.

For CLAT aspirants, the deeper lesson is about how law adapts to technology. The Drugs and Cosmetics Act was written in 1940 — decades before the structure of DNA was even known. That its subordinate rules can be amended to accommodate CAR-T therapy in 2026 speaks to the flexibility of delegated legislation, and to the enduring importance of Parliament’s power to authorise rule-making bodies to keep pace with a changing world.

Test Yourself — Daily Quiz